The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Pierre Rigo - One of the best experts on this subject based on the ideXlab platform.
-
Staging of the mediastinum value of positron emission tomography imaging in non small cell lung cancer
European Respiratory Journal, 1996Co-Authors: Thierry Bury, P Paulus, A Dowlati, Jeanlouis Corhay, T Weber, Benoit Ghaye, J Schoffers, Raymond Limet, Adelin Albert, Pierre RigoAbstract:Recent studies have shown limitations of morphological imaging in Staging mediastinal lymph node involvement in lung cancer. In contrast to computed tomography (CT), which depends primarily on anatomical imaging features, positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) depends mainly on the metabolic characteristics of a tissue for the diagnosis of disease. We have performed a prospective study comparing FDG-PET and CT of the thorax in the presurgical assessment of the mediastinum in 50 patients with newly diagnosed non-small cell lung cancer (NSCLC). CT and PET scans were interpreted separately, and results were compared to Pathological Staging obtained during thoracotomy. Hilar or mediastinal lymph node involvement was present in 58%. In Staging for lymph node involvement, CT had a sensitivity of 72% and specificity of 81%, whereas PET had a sensitivity and specificity of 90% and 86%, respectively. When the PET study was compared to histological results, there were four cases showing more advanced mediastinal involvement with PET and four cases showing less involvement with PET. From our preliminary results, we conclude that positron emission tomography with 18-fluorodeoxyglucose is significantly more accurate than computed tomography in the mediastinal Staging of non-small cell lung cancer.
Thomas J Meyer - One of the best experts on this subject based on the ideXlab platform.
-
neoadjuvant chemoradiation therapy with gemcitabine cisplatin and surgery versus immediate surgery in resectable pancreatic cancer results of the first prospective randomized phase ii trial
Strahlentherapie Und Onkologie, 2015Co-Authors: Henriette Golcher, B Thomas M D Brunner, Helmut Witzigmann, M Lukas D Marti, W O Bechstein, Christiane J Bruns, M Henry D Jungnickel, M Stefan D Schreiber, Gerhard G Grabenbauer, Thomas J MeyerAbstract:Background In nonrandomized trials, neoadjuvant treatment was reported to prolong survival in patients with pancreatic cancer. As neoadjuvant chemoradiation is established for the treatment of rectal cancer we examined the value of neoadjuvant chemoradiotherapy in pancreatic cancer in a randomized phase II trial. Radiological Staging defining resectability was basic information prior to randomization in contrast to adjuvant therapy trials resting on Pathological Staging.
Brian C Mccaughan - One of the best experts on this subject based on the ideXlab platform.
-
node negative non small cell lung cancer Pathological Staging and survival in 1765 consecutive cases
Journal of Thoracic Oncology, 2011Co-Authors: Benjamin M Robinson, Catherine Kennedy, Jocelyn Mclean, Brian C MccaughanAbstract:Introduction This study aimed to evaluate prognostic factors in patients with node-negative non-small cell lung cancer and to assess revised International Association for the Study of Lung Cancer Staging recommendations for this group. Methods A retrospective analysis of 1765 consecutive Pathologically node-negative patients treated by surgical resection between 1984 and 2007 was performed. Survival analysis was conducted using the Kaplan-Meier method. The independence of prognostic factors was analyzed using multivariate Cox proportional hazards modeling. Results The median age of patients was 68 years, and the average length of follow-up was 6.3 years. Perioperative mortality was 1.7%. The median survival was 6.5 years, with a 56% of the cohort surviving 5 years. Factors associated with poorer prognosis were male gender (hazard ratio [HR]: 1.30, p = Conclusions In surgically treated, node-negative non-small cell lung cancer, revised International Association for the Study of Lung Cancer Staging criteria stratify survival well. Age, gender, and extent of resection are also important predictors of survival. Current T-stage descriptor groupings are appropriate.
David J Harrison - One of the best experts on this subject based on the ideXlab platform.
-
who isup classification grading and Pathological Staging of renal cell carcinoma standards and controversies
World Journal of Urology, 2018Co-Authors: Anne Y Warren, David J HarrisonAbstract:Pathological parameters assessed on biopsies and resection specimens have a pivotal role in the diagnosis, prognosis and management of patients with renal cell carcinoma (RCC). A non-systematic literature search was performed, updated to January 2018, to identify key standards and controversies in the Pathological classification, grading and Staging of RCC. Although most RCCs exhibit characteristic morphology that enables easy categorisation, RCCs show considerable morphological heterogeneity and it is not uncommon for there to be difficulty in assigning a tumour type, especially with rarer tumour subtypes. The differentiation between benign and malignant oncocytic tumours remains a particular challenge. The development of additional immunohistochemical and molecular tests is needed to facilitate tumour typing, because of the prognostic and therapeutic implications, and to enable more reliable identification of poorly differentiated metastatic tumours as being of renal origin. Any new tests need to be applicable to small biopsy samples, to overcome the heterogeneity of renal tumours. There is also a need to facilitate identification of tumour types that have genetic implications, to allow referral and management at specialist centres. Digital pathology has a potential role in such referral practice. Much has been done to standardise Pathological assessment of renal cell carcinomas in recent years, but there still remain areas of difficulty in classification and grading of these heterogeneous tumours.
Tim J Kennedy - One of the best experts on this subject based on the ideXlab platform.
-
factors influencing adrenal metastasis in renal cell carcinoma
The Journal of Urology, 1994Co-Authors: Arthur I Sagalowsky, Keith T Kadesky, David Ewalt, Tim J KennedyAbstract:AbstractThe factors predisposing to adrenal metastasis in renal cell carcinoma were reviewed in 695 cases. The overall incidence of adrenal metastasis was 4.3%. The risk of adrenal metastasis correlated with tumors that were on the left side, large and replacing the entire kidney, upper pole in location and of advanced Τ stage. Nevertheless, microscopic and/or contralateral adrenal metastasis was noted in patients with smaller, lower pole or mid renal tumors. Of 30 patients with adrenal metastasis 9 (30%) had clinical evidence of widespread disease. Among the patients who underwent complete surgical resection 14% had either positive lymph nodes or other nonadrenal metastases. Of the patients undergoing resection 81% died, with a mean postoperative survival of 27 months. Sustained disease-free survival was noted in 3 patients (0.43% of the entire series) whose complete Pathological Staging was pT1-3b, N0, M0. The need and benefit of adrenalectomy during surgery for renal cell carcinoma are extremely limited.